Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)
ID: 336829Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336829

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-22-074.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) grant, aimed at promoting innovative interdisciplinary research in benign urologic conditions, with a current focus on neurourology. This program invites R01 grant applications for basic, translational, and clinical research that addresses neural mechanisms contributing to urologic diseases, emphasizing the importance of collaboration among diverse research teams, including early-stage investigators. The NIH has allocated an annual budget of $1,125,000 for approximately three awards per fiscal year, with applications accepted until May 7, 2025. Interested applicants can find more information and guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAS-22-074-Full-Announcement.html
    PAS-22-074.html
    The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), aims to foster innovative and interdisciplinary research addressing benign urologic conditions, focusing specifically on neurourology. This program invites R01 grant applications for studies spanning basic, translational, and clinical research, especially on neural mechanisms contributing to urologic diseases. Key dates for application submissions span from February 2022 through February 2025, with an annual budget of $1,125,000 designated for approximately three awards per fiscal year. Eligible applicants include diverse educational institutions, non-profits, for-profit organizations, and government entities, emphasizing collaboration among interdisciplinary teams and the participation of early-stage investigators. The applications must adhere strictly to stipulated guidelines, covering aspects like research strategy, budget justification, and inclusion plans for diverse populations. This grant aims to close knowledge gaps in urologic diseases, thus promoting better prevention, diagnosis, and treatment strategies, contributing to improved patient outcomes. The focus on multifaceted research approaches underscores the NIDDK’s commitment to addressing complex health issues in urology.
    Similar Opportunities
    Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Urology Centers Program Interactions Core (U24), aimed at enhancing collaboration and coordination within the urological research community. This initiative seeks to promote innovative, interdisciplinary research on benign urological diseases while supporting the training of emerging researchers through productive partnerships among the U54 and P20 Centers, career development programs, and external investigators. The program emphasizes inclusion and equal opportunity among applicants, with funding available up to $500,000, and applications are due by November 21, 2024, with potential funding commencing shortly thereafter. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-002.html.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Network Award (U2C) to enhance training in kidney, urologic, and hematologic research. This funding opportunity aims to foster a collaborative environment by inviting institutions to submit a unified application that supports a cohort of trainees and early-career investigators, with a strong emphasis on partnerships among institutions within metropolitan areas. The initiative is crucial for reshaping research training and promoting scientific collaboration, ensuring that the next generation of researchers is equipped to address complex biomedical challenges. Applications will be accepted starting October 16, 2023, with a submission deadline of September 27, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Biology of Bladder Cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research into the biology of bladder cancer through the R21 Clinical Trial Optional grant program. This initiative aims to support applications that investigate the molecular mechanisms and biological processes underlying bladder cancer, a significant health issue due to its high incidence and recurrence rates. The program encourages multidisciplinary research that utilizes clinical specimens and explores both normal and cancerous bladder processes, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including various educational and community organizations, must submit their proposals by September 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Biology of Bladder Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biology of Bladder Cancer (R01 Clinical Trial Optional)" aimed at advancing research into the biological mechanisms underlying bladder cancer. This initiative seeks applications that investigate various aspects of bladder cancer, including its initiation, progression, and the molecular changes associated with the disease, with a focus on enhancing understanding to develop new interventions. Given the significant health burden posed by bladder cancer, characterized by high incidence and recurrence rates, this research is crucial for improving survival rates and addressing disparities in outcomes among different populations. Eligible applicants include a wide range of institutions and organizations, with no budget limit for projects that can last up to five years. Interested parties can find more information and application guidelines at the NIH website, and the application deadline is September 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding pharmacodynamic, pharmacokinetic, and in vivo efficacy studies for novel therapeutic agents targeting neurological and neuromuscular disorders. This funding opportunity encourages diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to develop innovative therapeutic approaches that demonstrate significant improvements over existing treatments. With funding available up to $499,000 per year and a maximum of $750,000 over three years, applicants must adhere to rigorous scientific standards and collaborate with multidisciplinary teams. Interested parties should note that the application deadline is October 21, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.